As mentioned in the “Methods” section, the Japanese guidelines at that time and guidelines from other countries [31, 32] recommended RAASis for patients with hypertension and diabetes mellitus, reflecting the results of previous studies that showed the positive effect of decreasing intraglomerular pressure [33] or the antiglycemic effect in a kind of angiotensin-converting enzyme inhibitor [34]. The gene discussed is ACE; the disease is diabetes mellitus.